ACRO Biomedical Co Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $210.15 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
ACRO Biomedical Co Ltd had its IPO on under the ticker symbol ACBM.
The company operates in the Healthcare sector and Biotechnology industry. ACRO Biomedical Co Ltd has a staff strength of 0 employees.
Shares of ACRO Biomedical Co Ltd opened at $3.01 at the start of the last trading session i.e. 2023-03-23.
The stocks traded within a range of $3 - $3.01, and closed at $3.
This is a -10.18% slip from the previous day's closing price.
A total volume of 600 shares were traded at the close of the day’s session.
In the last one week, shares of ACRO Biomedical Co Ltd have slipped by -14.29%.
ACRO Biomedical Co Ltd's Key Ratios
ACRO Biomedical Co Ltd has a market cap of $210.15 million, indicating a price to book ratio of 487.9837 and a price to sales ratio of 267.8951.
In the last 12-months ACRO Biomedical Co Ltd’s revenue was $896500 with a gross profit of $259500 and an EBITDA of $0. The EBITDA ratio measures ACRO Biomedical Co Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ACRO Biomedical Co Ltd’s operating margin was -1761.12% while its return on assets stood at -1549.74% with a return of equity of -2978.09%.
In Q3, ACRO Biomedical Co Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 200%.
ACRO Biomedical Co Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ACRO Biomedical Co Ltd’s profitability.
ACRO Biomedical Co Ltd stock is trading at a EV to sales ratio of 267.9128 and a EV to EBITDA ratio of -15.2126. Its price to sales ratio in the trailing 12-months stood at 267.8951.
ACRO Biomedical Co Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
ACRO Biomedical Co Ltd ended 2023 with $643648.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $643648.00 while shareholder equity stood at $492164.00.
ACRO Biomedical Co Ltd ended 2023 with $0 in deferred long-term liabilities, $144958.00 in other current liabilities, 60042.00 in common stock, $-19873244.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16188.00 and cash and short-term investments were $16188.00. The company’s total short-term debt was $0 while long-term debt stood at $0.
ACRO Biomedical Co Ltd’s total current assets stands at $607428.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $278500.00 compared to accounts payable of $99494.00 and inventory worth $296000.00.
In 2023, ACRO Biomedical Co Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, ACRO Biomedical Co Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
ACRO Biomedical Co Ltd stock is currently trading at $3 per share. It touched a 52-week high of $4.8 and a 52-week low of $4.8. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $3.72 and 200-day moving average was $3.98 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4996.5% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About ACRO Biomedical Co Ltd
Similar Industry Stocks (Biotechnology)
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana.